Thrombocytosis in asplenia syndrome with congenital heart disease: A previously unrecognized risk factor for thromboembolism

Kenichiro Yamamura, Kunitaka Joo, Shoichi Ohga, Hazumu Nagata, Kazuyuki Ikeda, Jun Muneuchi, Mamie Watanabe, Toshiro Hara

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Thrombocytosis and thromboembolic complications occur after splenectomy. However, there is no previous report investigating the presence of thrombocytosis and its association with thromboembolic events in patients having asplenia syndrome with congenital heart disease. Methods: Enrolled were 161 consecutive patients with functionally single ventricle who underwent cardiac catheterization between 1997 and 2010. They were divided into two groups: patients having asplenia (Group A, n = 46) and patients having no asplenia (Group B, n = 115). Aspirin therapy was employed in all patients after surgical interventions except for pulmonary artery banding. We retrospectively reviewed the platelet counts at each seven stage of cardiac catheterization (for pre- and postoperative evaluation of the first palliation, Glenn operation, and Fontan operation, and for late evaluation after Fontan operation), incidence of thromboembolic events, and other possible risk factors for thromboembolism. Results: The median platelet counts in Group A were consistently higher than those in Group B at any of the seven stages of cardiac catheterizations (p < 0.002). The incidence of thromboembolic complications was also higher in Group A than that in Group B (28% vs. 10%, p = 0.030). Univariate and multivariate logistic regression analyses showed that a platelet count of more than 550 × 109/L at the first cardiac catheterization was associated with thromboembolic complications (Odds ratio 3.17; p = 0.046). Conclusions: Persistent thrombocytosis is present in patients with asplenia syndrome. It may greatly contribute to the development of thromboembolism during the management of congenital heart disease than expected.

Original languageEnglish
Pages (from-to)2259-2263
Number of pages5
JournalInternational Journal of Cardiology
Volume167
Issue number5
DOIs
Publication statusPublished - Sep 1 2013

Fingerprint

Heterotaxy Syndrome
Thrombocytosis
Thromboembolism
Heart Diseases
Cardiac Catheterization
Platelet Count
Fontan Procedure
Incidence
Splenectomy
Pulmonary Artery
Aspirin
Logistic Models
Odds Ratio
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Thrombocytosis in asplenia syndrome with congenital heart disease : A previously unrecognized risk factor for thromboembolism. / Yamamura, Kenichiro; Joo, Kunitaka; Ohga, Shoichi; Nagata, Hazumu; Ikeda, Kazuyuki; Muneuchi, Jun; Watanabe, Mamie; Hara, Toshiro.

In: International Journal of Cardiology, Vol. 167, No. 5, 01.09.2013, p. 2259-2263.

Research output: Contribution to journalArticle

Yamamura, Kenichiro ; Joo, Kunitaka ; Ohga, Shoichi ; Nagata, Hazumu ; Ikeda, Kazuyuki ; Muneuchi, Jun ; Watanabe, Mamie ; Hara, Toshiro. / Thrombocytosis in asplenia syndrome with congenital heart disease : A previously unrecognized risk factor for thromboembolism. In: International Journal of Cardiology. 2013 ; Vol. 167, No. 5. pp. 2259-2263.
@article{e14526293ac14928999be8946d4d2642,
title = "Thrombocytosis in asplenia syndrome with congenital heart disease: A previously unrecognized risk factor for thromboembolism",
abstract = "Background: Thrombocytosis and thromboembolic complications occur after splenectomy. However, there is no previous report investigating the presence of thrombocytosis and its association with thromboembolic events in patients having asplenia syndrome with congenital heart disease. Methods: Enrolled were 161 consecutive patients with functionally single ventricle who underwent cardiac catheterization between 1997 and 2010. They were divided into two groups: patients having asplenia (Group A, n = 46) and patients having no asplenia (Group B, n = 115). Aspirin therapy was employed in all patients after surgical interventions except for pulmonary artery banding. We retrospectively reviewed the platelet counts at each seven stage of cardiac catheterization (for pre- and postoperative evaluation of the first palliation, Glenn operation, and Fontan operation, and for late evaluation after Fontan operation), incidence of thromboembolic events, and other possible risk factors for thromboembolism. Results: The median platelet counts in Group A were consistently higher than those in Group B at any of the seven stages of cardiac catheterizations (p < 0.002). The incidence of thromboembolic complications was also higher in Group A than that in Group B (28{\%} vs. 10{\%}, p = 0.030). Univariate and multivariate logistic regression analyses showed that a platelet count of more than 550 × 109/L at the first cardiac catheterization was associated with thromboembolic complications (Odds ratio 3.17; p = 0.046). Conclusions: Persistent thrombocytosis is present in patients with asplenia syndrome. It may greatly contribute to the development of thromboembolism during the management of congenital heart disease than expected.",
author = "Kenichiro Yamamura and Kunitaka Joo and Shoichi Ohga and Hazumu Nagata and Kazuyuki Ikeda and Jun Muneuchi and Mamie Watanabe and Toshiro Hara",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/j.ijcard.2012.06.009",
language = "English",
volume = "167",
pages = "2259--2263",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "5",

}

TY - JOUR

T1 - Thrombocytosis in asplenia syndrome with congenital heart disease

T2 - A previously unrecognized risk factor for thromboembolism

AU - Yamamura, Kenichiro

AU - Joo, Kunitaka

AU - Ohga, Shoichi

AU - Nagata, Hazumu

AU - Ikeda, Kazuyuki

AU - Muneuchi, Jun

AU - Watanabe, Mamie

AU - Hara, Toshiro

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Background: Thrombocytosis and thromboembolic complications occur after splenectomy. However, there is no previous report investigating the presence of thrombocytosis and its association with thromboembolic events in patients having asplenia syndrome with congenital heart disease. Methods: Enrolled were 161 consecutive patients with functionally single ventricle who underwent cardiac catheterization between 1997 and 2010. They were divided into two groups: patients having asplenia (Group A, n = 46) and patients having no asplenia (Group B, n = 115). Aspirin therapy was employed in all patients after surgical interventions except for pulmonary artery banding. We retrospectively reviewed the platelet counts at each seven stage of cardiac catheterization (for pre- and postoperative evaluation of the first palliation, Glenn operation, and Fontan operation, and for late evaluation after Fontan operation), incidence of thromboembolic events, and other possible risk factors for thromboembolism. Results: The median platelet counts in Group A were consistently higher than those in Group B at any of the seven stages of cardiac catheterizations (p < 0.002). The incidence of thromboembolic complications was also higher in Group A than that in Group B (28% vs. 10%, p = 0.030). Univariate and multivariate logistic regression analyses showed that a platelet count of more than 550 × 109/L at the first cardiac catheterization was associated with thromboembolic complications (Odds ratio 3.17; p = 0.046). Conclusions: Persistent thrombocytosis is present in patients with asplenia syndrome. It may greatly contribute to the development of thromboembolism during the management of congenital heart disease than expected.

AB - Background: Thrombocytosis and thromboembolic complications occur after splenectomy. However, there is no previous report investigating the presence of thrombocytosis and its association with thromboembolic events in patients having asplenia syndrome with congenital heart disease. Methods: Enrolled were 161 consecutive patients with functionally single ventricle who underwent cardiac catheterization between 1997 and 2010. They were divided into two groups: patients having asplenia (Group A, n = 46) and patients having no asplenia (Group B, n = 115). Aspirin therapy was employed in all patients after surgical interventions except for pulmonary artery banding. We retrospectively reviewed the platelet counts at each seven stage of cardiac catheterization (for pre- and postoperative evaluation of the first palliation, Glenn operation, and Fontan operation, and for late evaluation after Fontan operation), incidence of thromboembolic events, and other possible risk factors for thromboembolism. Results: The median platelet counts in Group A were consistently higher than those in Group B at any of the seven stages of cardiac catheterizations (p < 0.002). The incidence of thromboembolic complications was also higher in Group A than that in Group B (28% vs. 10%, p = 0.030). Univariate and multivariate logistic regression analyses showed that a platelet count of more than 550 × 109/L at the first cardiac catheterization was associated with thromboembolic complications (Odds ratio 3.17; p = 0.046). Conclusions: Persistent thrombocytosis is present in patients with asplenia syndrome. It may greatly contribute to the development of thromboembolism during the management of congenital heart disease than expected.

UR - http://www.scopus.com/inward/record.url?scp=84883261776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883261776&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2012.06.009

DO - 10.1016/j.ijcard.2012.06.009

M3 - Article

C2 - 22727971

AN - SCOPUS:84883261776

VL - 167

SP - 2259

EP - 2263

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 5

ER -